Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

STLN vs XLO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XLO Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 8–1 Matrix Metrics)

XLO Overall Winner 6-Pillar Tally: STLN 0 – 4 XLO (2 Tie) Matrix Metrics: STLN 1 – 8 XLO

As of Nov 20, 2026, Xilio Therapeutics, Inc. (XLO) is the stronger overall head-to-head candidate over STLN (STLN) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). STLN carries a Unified Composite Score of 46.6/100 (HOLD) at $3.00 (N/M Forward P/E, N/A operating margin), whereas XLO carries 45.8/100 (HOLD) at $7.56 (N/M Forward P/E, -74.9% operating margin).

  • Composite vs. Pillar Nuance: While STLN currently prints a higher short-term Unified Composite Score (46.6/100 HOLD vs. XLO 45.8/100 HOLD), XLO captures the overall institutional head-to-head verdict (8–1 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-74.9% vs. N/A operating margin) and revenue trajectory (-47.6% vs. N/A YoY).
  • Technical & Structure Timing Caution: STLN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.4); meanwhile XLO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About STLN vs XLO
STLN US Equity
STLN
Institutional Equity
$3.00
-5.66% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.42β · 175% Vol
Unified Composite Score
46.6 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.2%), weak momentum, RSI 26
RSI-14: 26.4 · SMA20: $4.93 · SMA50: $5.93
XLO NASDAQ Head-to-Head Winner
Xilio Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$7.56
+0.67% 1D
Market Cap $53.1M
TTM Revenue $55M
Forward P/E N/M
Beta / 30D Vol 0.74β · 63% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 50.0 Mom 74.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.4%), weak momentum, RSI 38
RSI-14: 37.9 · SMA20: $8.09 · SMA50: $8.56

6-Pillar Scorecard Institutional Category Breakdown (STLN 0 – 4 XLO)

Columns: Metric · STLN · XLO
1. Valuation Multiples XLO
Forward P/E N/M N/M
Trailing P/E N/M 11.6x
PEG Ratio N/M N/M
EV / Revenue N/M 1.0x
2. Growth & Scale XLO
Revenue Growth (YoY) N/A -47.6%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $55M
Market Cap N/A $53.1M
3. Profitability & Quality XLO
Gross Margin N/A 79.5%
Operating Margin N/A -74.9%
Net Profit Margin N/A -20.9%
Return on Equity (ROE) N/A -38.2%
4. Balance Sheet & Cash Flow XLO
Cash Generation (TTM) N/A -$40M EBITDA
Cash Flow Margin N/A -72.5% EBITDA Mgn
Net Cash / Leverage N/A ROE $10.36 Book/Sh · -38.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: STLN (1) vs XLO (8)
Institutional Metric STLN XLO Criterion Row Edge
Market Capitalization
Scale
N/A $53.1M Larger Scale XLO
Trailing P/E Ratio
Valuation
N/M 11.6x Lower Multiple XLO
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -47.6% Higher Growth XLO
Operating Margin (TTM)
Profitability
N/A -74.9% Higher Margin XLO
Net Profit Margin
Profitability
N/A -20.9% Higher Margin XLO
Return on Equity (ROE)
Capital Efficiency
N/A -38.2% Higher ROE XLO
52-Week Range Position
Momentum
1% ($3–$7) 75% ($0–$10) Stronger Trend XLO
Beta / 30D Volatility
Risk Regime
1.42β · 175% Vol 0.74β · 63% Vol Lower Realized Risk XLO
Unified Institutional Score
Composite Signal
46.6 / 100 (HOLD) 45.8 / 100 (HOLD) Higher Composite STLN
Trailing 12M Revenue (USD)
Operating Scale
N/A $55M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 79.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$40M EBITDA ($10.36 Book/Sh · -38.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XLO +50.73 pp
STLN: -56.58% · XLO: -5.85%
3M Horizon XLO +33.32 pp
STLN: -51.06% · XLO: -17.74%
6M Horizon XLO +25.14 pp
STLN: -41.97% · XLO: -16.83%
1Y Horizon XLO +25.14 pp
STLN: -41.97% · XLO: -16.83%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on STLN vs XLO. Trailing 12-month operating profitability (STLN N/A vs XLO -74.9%) and valuation multiples (STLN N/M vs XLO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

STLN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
XLO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$55M
Gross Margin79.5%
Op. Margin-74.9%
ROE / Fwd P/E-38.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
STLN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact STLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XLO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XLO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
STLN Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
XLO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $53.1M market capitalization and -74.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ STLN vs XLO Key Questions & Quantitative Answers

As of Nov 20, 2026, Xilio Therapeutics, Inc. (XLO) is the stronger overall head-to-head candidate over STLN (STLN) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). STLN carries a Unified Composite Score of 46.6/100 (HOLD) at $3.00 (N/M Forward P/E, N/A operating margin), whereas XLO carries 45.8/100 (HOLD) at $7.56 (N/M Forward P/E, -74.9% operating margin). Composite vs. Pillar Nuance: While STLN currently prints a higher short-term Unified Composite Score (46.6/100 HOLD vs. XLO 45.8/100 HOLD), XLO captures the overall institutional head-to-head verdict (8–1 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-74.9% vs. N/A operating margin) and revenue trajectory (-47.6% vs. N/A YoY). Technical & Structure Timing Caution: STLN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.4); meanwhile XLO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XLO leads the Growth & Scale pillar: STLN posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with XLO at -47.6% YoY revenue growth and +0.0% YoY earnings growth on $55M TTM revenue (79.5% gross margin, -74.9% operating margin). On trailing 12-month operating scale, STLN generates N/A in USD-normalized revenue versus $55M for XLO. In operating R&D and SG&A reinvestment, STLN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XLO.

XLO screens cheaper on headline valuation multiples. STLN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas XLO trades at N/M Forward P/E, 11.6x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (-72.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against STLN (N/A ROE) versus XLO (-38.2% ROE) capital efficiency.

In options market volatility and institutional positioning, STLN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.42β · 175% Vol realized risk). By comparison, XLO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.74β · 63% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.